Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Pelacarsen Roll-over Extension Program |
Atherosclerotic Cardiovascular Disease | Phase3 | Puerto Rico United States |
NCT06875973 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Brazil Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Romania Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines |
Chronic Spontaneous Urticaria (CSU) | Phase3 | United States | NCT06868212 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | South Korea | NCT05943522 | |
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia |
Myeloid Leukemia, Philadelphia Positive | Phase1, Phase2 | China France Germany Greece Hungary Italy Japan Netherlands Poland Russia South Korea Thailand Turkey (Türkiye) United States View all |
NCT04925479 |
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
Primary IgA Nephropathy | Phase3 | Brazil Mexico United States |
NCT04557462 |
Home Reported Outcomes in C3G Study |
C3 Glomerulopathy | United States | NCT07029542 | |
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase1, Phase2 | Australia Canada Czechia Denmark France Germany Israel Italy Japan Singapore South Korea Spain Taiwan United Kingdom United States View all |
NCT06726148 |
Phase 2 Study of Rapcabtagene Autoleucel in Myositis |
Idiopathic Inflammatory Myopathies | Phase2 | France Germany Israel Italy Japan Netherlands Saudi Arabia Singapore Spain Switzerland Taiwan United Kingdom United States View all |
NCT06665256 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |